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Summary
When humans are exposed to hypoxia, systemic and intra-
cellular changes operate together to minimise hypoxic injury
and restore adequate oxygenation. Emerging evidence indi-
cates that the hypoxia-inducible factor (HIF) family of
transcription factors plays a central regulatory role in these
homeostatic changes at both the systemic and cellular levels.
HIF was discovered through its action as the transcriptional
activator of erythropoietin, and has subsequently been found
to control intracellular hypoxic responses throughout the
body. HIF is primarily regulated by speciﬁc prolyl hydrox-
ylase-domain enzymes (PHDs) that initiate its degradation
via the von Hippel-Lindau tumour suppressor protein
(VHL). The oxygen and iron dependency of PHD activity
accounts for regulation of the pathway by both cellular
oxygen and iron status. Recent studies conducted in patients
with rare genetic diseases have begun to uncover the wider
importance of the PHD-VHL-HIF axis in systems-level
human biology. These studies indicate that, in addition to
regulating erythropoiesis, the system plays an important role
in cardiopulmonary regulation. This article reviews our
current understanding of the importance of HIF in human
systems-level physiology, and is modelled around the classic
physiological response to high-altitude hypoxia.
Keywords: erythropoietin, erythropoiesis, polycythaemia,
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The human response to hypoxia is characterised by systemic
changes in haematopoietic, respiratory, and cardiovascular
physiology that combine to restore adequate oxygenation.
Uptake and transport of oxygen are initially maximised
through an increase in ventilation and cardiac output, while
oxygen carriage is subsequently optimised through acceleration
of erythropoiesis. The homeostatic drive underlying these
systemic effects is similarly evident at the cellular level, where
hypoxia is met by a coordinated transcriptional response that
seeks to minimise hypoxic injury and redress the oxygen debt.
This cellular response is controlled by the hypoxia-inducible
factor (HIF) family of transcription factors, a DNA binding
complex that was ﬁrst deﬁned as a regulator of erythropoietin
(Epo) gene (EPO) expression but which is now known to be
conserved in all animal species, irrespective of the presence of
specialised oxygen transfer systems such as the lungs, heart,
and blood (Semenza, 2004). Studies at the cellular level
indicate that HIF directly or indirectly regulates several
hundred genes that serve a great variety of functional pathways
including angiogenesis, cell growth, apoptosis, energy metab-
olism and vasomotor regulation (Semenza, 2004). Recent
studies in humans have also demonstrated a major role in
systemic responses to hypoxia that extends to each of the
principal organ systems upon which cellular oxygen delivery
ultimately depends. This article reviews our current under-
standing of the importance of HIF in human systems-level
physiology, and is modelled around the classic physiological
response to high-altitude hypoxia. Readers are referred to
other reviews for detailed analyses of the interaction between
HIF and cancer biology (Patiar & Harris, 2006), angiogenesis
(Hirota & Semenza, 2006) and therapeutics (Hewitson &
Schoﬁeld, 2004; Semenza, 2006).
Integrative human hypoxia physiology: the
response to high altitude
Lowland residents travelling to high altitude experience
profound physiological changes as a result of environmental
hypoxia. This acclimatisation process conveniently demon-
strates the systemic effects of isolated hypoxia, which are less
pleiotropic than might be expected from the great functional
diversity present within the HIF-regulated transcriptome.
Haematological, respiratory and cardiovascular responses
predominate and are described in this section.
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Though slower in onset than its cardiopulmonary counter-
parts, the development of polycythaemia has been the most
widely known feature of acclimatisation since Viault ﬁrst
reported a proliferative effect of high altitude on his own red
cell count (Viault, 1890). After years of subsequent conjecture,
the existence of a humoral erythropoietic factor was eventually
proven in rabbits by transfusing normal animals with plasma
from severely anaemic donors (Erslev, 1953), although human
Epo was not isolated at sufﬁcient purity to obtain a partial
protein sequence until 1977. Hypoxia generates a detectable
increase in serum Epo within 90 min (Eckardt et al, 1989).
Following ascent to high altitude, Epo levels peak within 2 d
and thereafter decline towards sea-level values over a period of
1–2 weeks (Abbrecht & Littell, 1972; Milledge & Cotes, 1985;
Richalet et al, 1994). This decline occurs despite ongoing
hypoxia and notably precedes most of the expansion of red cell
mass. Haemoglobin (Hb) and haematocrit (Hct) are never-
theless elevated within days of ascent (Richalet et al, 1994) and
red cell mass has been shown to continue rising for up to eight
months and, for an altitude of 4500 m, approach a total
increase of 50% (Reynafarje et al, 1959). The polycythaemic
response is therefore largely developed and maintained in the
presence of relatively normal levels of Epo, as is the case when
secondary polycythaemia results from hypoxic lung disease
(Wedzicha et al, 1985). The maximum expansion in red cell
mass varies with the severity of hypoxia – at extreme altitudes,
Hb > 210 g/l and Hct > 60% have been reported in acclima-
tising individuals (Winslow et al, 1984). Values are naturally
higher in high altitude natives, and for Andean males the
normal Hb has been related to the arterial partial pressure of
oxygen through an empirically-derived function, as depicted in
Fig 1. Because of this relationship, the magnitude of erythro-
cytosis that is considered excessive and deﬁnes chronic
mountain sickness varies with altitude.
Ventilatory acclimatisation to hypoxia
Pulmonary ventilation is closely coupled to energy metabolism
in the body, simultaneously providing an essential substrate
(oxygen) and removing a major by-product (carbon dioxide),
and ventilation is duly inﬂuenced by changes in the arterial
partial pressures of both oxygen (Po2) and carbon dioxide
(Pco2). Experimental investigations into the respiratory effects
of high altitude hypoxia date back to Angelo Mosso’s
pioneering experiments in the Italian Alps in the 1890’s (West,
1998). In 1911 the landmark Oxford-Yale expedition to Pike’s
Peak, Colorado (altitude 4300 m), conﬁrmed the earlier
observation that alveolar Pco2 declines at altitude and
demonstrated an increase in alveolar Po2 as a result of
hyperventilation (Douglas et al, 1913). It is now well known
that acute hypoxia stimulates an immediate increase in minute
ventilation that peaks within minutes and then declines
towards prehypoxic levels over the following minutes-
to-hours. When hypoxia is sustained, as at high altitude,
ventilation begins to rise again after an hour or two, soon
surpassing acute hypoxic levels and continuing to rise for
several days. This progressive increase in ventilation is known
as ventilatory acclimatisation to hypoxia, and the resultant
elevation in arterial Po2 mitigates the impact of environmental
hypoxia. The characteristic features of ventilatory acclimatisa-
tion include a concomitant fall in Pco2, and an increase in
hypoxic ventilatory sensitivity that heightens the ventilatory
response to any further acute hypoxic stimulus (Douglas et al,
1913; Rahn & Otis, 1949; Sato et al, 1992).
Hypoxia-induced changes in cardiac output
Acute hypoxia stimulates a reﬂex increase in cardiac output.
Pike’s Peak also provided the setting for the ﬁrst high altitude
measurements of cardiac output, where the acetylene gas
uptake technique was used to demonstrate a progressive
increase in cardiac output over several days (Grollman, 1930).
This increase is associated with an elevation in heart rate rather
than stroke volume (Vogel & Harris, 1967). Cardiac output
gradually normalises as individuals acclimatise, although heart
rate may remain high accompanied by a lower stroke volume.
Pulmonary vascular acclimatisation to hypoxia
In 1947, right heart catheterisation of volunteers breathing
10% oxygen provided the ﬁrst evidence that, in contrast with
other vascular beds, hypoxia constricts rather than dilates the
Fig 1. Empirically-derived relationship between haemoglobin con-
centration (Hb) and arterial partial pressure of oxygen (Pao2) in
Andean men. From Villafuerte et al (2004) (used with permission).
The average Hb of young high-altitude natives is represented by an
empirical equation that expresses Hb as a function of Pao2. This
equation was derived using data collated from several studies, which
investigated approximately 200 healthy men aged 18–45 years. Mea-
surements were largely made in members of the native Quechua
population at altitudes ranging from sea level to 4860 m, and Pao2 was
calculated from arterial haemoglobin oxygen saturation. Pao2 is pri-
marily determined by the altitude of residence, and for a given altitude,
a Hb of more than two standard deviations above average is considered
excessive (Villafuerte et al, 2004).
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acutely elevates pulmonary arterial pressure, which reaches
a plateau within 5 min (Talbot et al, 2005). Pulmonary arterial
pressure begins to increase again after approximately 45 min
(Talbot et al, 2005) and continues to rise for at least another
2 h (Dorrington et al, 1997). Pulmonary vascular acclimatisa-
tion is characterised by the resultant elevation in pulmonary
arterial pressure, and by an accompanying increase in the
sensitivity of the pulmonary vascular response to any addi-
tional acute hypoxic stimulus (Dorrington et al, 1997).
Although this pulmonary hypertensive response is a prom-
inent consequence of ascent to high altitude, unlike other
features of acclimatisation it is generally troublesome rather
than beneﬁcial. The underlying phenomenon of hypoxic
pulmonary vasoconstriction is of great importance during
foetal life. In utero, pulmonary perfusion needs only meet the
metabolic demands of the lung tissue itself, and vasoconstric-
tion in the relatively hypoxic unventilated lung is instrumental
in shunting oxygenated blood to the rest of the body via the
foetal circulation. Following delivery and aeration of the lungs,
rapid reversal of pulmonary vasoconstriction facilitates tran-
sition to the adult circulation, in which the systemic and
pulmonary vasculature are anatomically ‘in series’ and thus
virtually the entire cardiac output can participate in gas
exchange. In adults, regional hypoxic pulmonary vasocon-
striction can be beneﬁcial in matching perfusion to ventilation
throughout the lung (eg in single lung anaesthesia), although
under normal conditions its contribution to maintaining Po2
over the physiological range remains uncertain (Dorrington &
Talbot, 2004). Global hypoxic pulmonary vasoconstriction
involving the entire lung is commonly undesirable as it
eventually leads to pulmonary vascular remodelling and
pulmonary hypertension, which frequently complicates hyp-
oxic lung disease and worsens survival of patients with
conditions such as chronic obstructive pulmonary disease
(Barbera et al, 2003). Hypoxia-induced pulmonary hyperten-
sion is also a major cause of morbidity in high altitude
residents, where it manifests in chronic and subacute moun-
tain sickness, while in non-residents it can acutely precipitate
high altitude pulmonary oedema, the most common cause of
death related to high altitude (Hackett & Roach, 2001;
Penaloza & Arias-Stella, 2007).
HIF transcriptional activation system
Over the past 15 years the role of HIF in cellular oxygen
signalling has been extensively investigated. The ﬁrst member of
the HIF family of transcription factors to be discovered, HIF-1,
was originally identiﬁed as a hypoxia-inducible nuclear factor
that bound to the hypoxia-response element enhancer region of
the Epo gene (Semenza & Wang, 1992). In accordance with the
effects of hypoxia on serum Epo, the DNA-binding activity of
HIF-1 was found to be tightly regulated by cellular oxygen
tension. Subsequent puriﬁcation revealed that HIF-1 was in fact
a heterodimer consisting of HIF-1a and HIF-1b subunits that
are both members of the basic helix-loop-helix PAS protein
family (Wang et al, 1995). Studies in cultured cells found that
cobalt chloride had a hypoxia-mimetic effect on HIF-1 and
expression of Epo RNA (Wang & Semenza, 1993a), consistent
with previous observations that cobalt causes polycythaemia in
humans. Desferrioxamine was also found to induce HIF-1
activity and EPO RNA expression with kinetics similar to that
of induction by hypoxia and cobalt chloride (Wang & Semenza,
1993b). Although initially studied extensively in the context of
Epo regulation, HIF-1 and its recognition sequence were soon
shown to be common components of a general mammalian
cellular response to hypoxia. Early studies demonstrated
oxygen-dependent DNA binding of HIF and transcriptional
activation of a hypoxia response element in a variety of cell lines
(Maxwell et al, 1993; Wang & Semenza, 1993a)and for a variety
of genes (Firth et al, 1994). Further experiments determined
that HIF-1b is constitutively expressed, is present in excess, is a
component of other transcription factors and is unaffected by
hypoxia, whereas HIF-1a is unique to HIF-1 and is the primary
determinant of HIF-1 DNA binding and transcriptional activity
(Huang et al, 1996; Jiang et al, 1996; Semenza et al, 1996). As
the list of HIF-regulated genes continued to grow steadily, more
detailed analyses determined that, under euoxic conditions,
HIF-1a is synthesised continuously but is rapidly degraded by
the ubiquitin-proteasome system via a process that requires the
presence of two sequences in HIF-1a termed oxygen-dependent
degradation domains (Huang et al, 1996, 1998; Pugh et al,
1997; Salceda & Caro, 1997). In addition to the HIF-1a protein,
two closely related proteins that also dimerise with HIF-1b were
identiﬁed termed HIF-2a (Tian et al, 1997) and HIF-3a (Gu
et al, 1998). HIF-2a has a more restricted expression proﬁle
than HIF-1a but has many similar functional characteristics
(Wiesener et al, 1998), while the regulation and functions of
HIF-3a are less well understood.
By this stage it was known that hypoxic stabilisation of HIF-a
subunits leads to their accumulation, but the oxygen sensor
responsibleforregulatingthisprocessremainedelusive.Amajor
advancefollowedfromtherecognitionthatHIF-targetgenesare
upregulated in tumours of the von Hippel-Lindau inherited
cancer syndrome, in which the von Hippel-Lindau tumour
suppressor protein (VHL) is mutated. Subsequent research
showed that VHL binds to the HIF-a subunit and targets it for
ubiquitin-mediated proteasomal degradation by acting as the
recognition component of a multiprotein ubiquitin ligase
complex (Maxwell et al, 1999; Cockman et al, 2000; Ohh et al,
2000). In 2001 the fundamental oxygen-sensitive step underly-
ing the degradation of HIF-a was deﬁned as oxygen-dependent
hydroxylation of speciﬁc proline residues in HIF-a, a modiﬁ-
cationthatdirectsthebindingofVHL(Ivanet al,2001;Jaakkola
et al, 2001; Yu et al, 2001). Three isoenzymes, termed prolyl
hydroxylase-domain (PHD) proteins, were subsequently iden-
tiﬁed that catalyse this prolyl hydroxylation of HIF-a (Epstein
et al, 2001). The three PHDs (PHD1, PHD2 and PHD3) are
members of the 2-oxoglutarate- and iron-dependent dioxy-
genase family of enzymes and their activity is dependent upon
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2-oxoglutarate as obligate cofactors.
Thus, under euoxic conditions HIF-a is continuously
expressed and rapidly degraded whereas under hypoxic
conditions, prolyl hydroxylation and proteasomal degradation
are slowed, resulting in stabilisation and accumulation of
HIF-a. The HIF-a subunit is then translocated to the nucleus
where it dimerises with HIF-b, binds to the hypoxia response
elements of HIF-target genes and activates their transcription.
Hypoxia-inducible factor-a undergoes a further post-
translational modiﬁcation that affects its transcriptional
activity rather than its stability. Hydroxylation of an aspar-
agine residue within the C-terminal transactivation domain of
HIF-a reduces its transcriptional activity by inhibiting
binding of the transcriptional coactivator complex p300/
CBP (Hewitson et al, 2002; Lando et al, 2002). This aspar-
aginyl hydroxylase, termed factor inhibiting HIF (FIH), also
belongs to the 2-oxoglutarate- and iron-dependent dioxygen-
ase superfamily and is similarly oxygen-dependent. Normal
mammalian cell and tissue oxygen tensions fall within the
sensitive range of PHD enzyme kinetics, such that small
changes in oxygen tension cause signiﬁcant changes in
enzymatic catalysis (Epstein et al, 2001; Hirsila et al, 2003).
FIH appears to have a ‘ﬁne-tuning’ role secondary to that of
the PHDs, exerting an additional level of negative control on
HIF-a that has escaped degradation (Stolze et al, 2004).
Although other signalling pathways interact with HIF and
affect the ultimate transcriptional response to hypoxia, the
PHD-VHL-HIF axis is now ﬁrmly established as the central
regulator of cellular oxygen homeostasis and is illustrated
schematically in Fig 2.
Initial evidence implicating HIF in systemic
physiology
The discovery of HIF, its ubiquity and the functional diversity
of its many target genes has inspired researchers to explore its
wider inﬂuence in systemic physiology. Early insights were
gained from experiments using genetically engineered mam-
malian models and from studies manipulating HIF pharma-
cologically in humans. In mice exposed to sustained hypoxia,
heterozygous deﬁciency for functional HIF genes delays the
development of polycythaemia (Yu et al, 1999) and prevents
normal ventilatory acclimatisation to both chronic hypoxia
(Kline et al, 2002) and intermittent hypoxia (Peng et al, 2006).
The development of hypoxia-induced pulmonary hypertension
and vascular remodelling are also markedly impaired in such
mice (Yu et al, 1999; Brusselmans et al, 2003), as are electro-
physiological responses to hypoxia in the pulmonary arterial
myocytes responsible for these processes (Shimoda et al, 2001).
Through intravenous infusions of desferrioxamine (DFO),
studies in humans sought to modify putative HIF-dependent
Fig 2. Schematic representation of the PHD-VHL-HIF axis. The hypoxia-inducible factor (HIF)-a subunit is synthesised continuously but is rapidly
destroyed in the presence of oxygen and iron. Oxygen- and iron-dependent prolyl hydroxylase domain (PHD) enzymes hydroxylate speciﬁc proline
residues in HIF-a, increasing its afﬁnity for the von Hippel-Lindau tumour suppressor protein (VHL). The binding of VHL to hydroxylated HIF-a
then targets HIF-a for destruction by a multiprotein ubiquitin ligase (denoted ‘ligase’) that mediates proteasomal degradation of HIF-a subunits.
Another oxygen- and iron-dependent enzyme, factor inhibiting HIF (FIH), hydroxylates an asparagine residue in HIF-a, reducing its ability to
activate transcription by inhibiting binding of the transcriptional coactivator complex p300/CBP. Under hypoxic conditions, the hydroxylation of
HIF-a by PHDs and FIH is inhibited and proteasomal degradation is thus slowed. HIF-a rapidly accumulates and dimerises with HIF-b, which is
expressed constitutively and is present in excess. The p300/CBP coactivator is recruited, and the DNA binding complex subsequently up-regulates
hypoxia-responsive genes. OH denotes hydroxyl group.
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effect that iron chelation has on HIF hydroxylation. In a study
of 16 subjects, an 8-h infusion of DFO increased serum Epo in
a dose-dependent manner but did not measurably affect
ventilatory sensitivity to acute hypoxia within 24 h of com-
mencing the infusion (Ren et al, 2000). However, research in
rats suggests that ventilatory effects may not be detectable until
2–3 d after administration of DFO (Nguyen et al, 2007). In
a further study, pulmonary vascular tone was assessed
echocardiographically in 20 subjects either during an infusion
of DFO or during exposure to hypoxia, and DFO was seen to
induce a mild elevation of pulmonary arterial pressure over
a similar time course to that associated with hypoxia (Balanos
et al, 2002).
Together these studies in animals and humans provided
indirect supportive evidence that HIF is important in human
cardiopulmonary physiology. In particular, these studies
introduced the possibility that HIF-regulated induction of
gene expression might mediate physiological responses to
sustained hypoxia, and that basal HIF activity might calibrate
the set point and sensitivity of systemic responses to an acute
hypoxic stimulus.
HIF and systemic human physiology
HIF and erythropoiesis
Much of what is known about the importance of HIF in
systemic human physiology has been learnt from phenotyping
haematology patients diagnosed with rare monogeneic disease.
The most extensively studied of these is Chuvash polycythae-
mia, a rare autosomal recessive disorder that was originally
described in the Chuvash population of Russia (Polyakova,
1974). Affected individuals are homozygous for a speciﬁc
598C>T mutation in the von Hippel-Lindau tumor suppressor
gene (VHL) that results in an amino acid change of arginine to
tryptophan (Ang et al, 2002). This diminishes the binding
afﬁnity of VHL for hydroxylated HIF-a, thereby subtly
inhibiting HIF-a degradation and pathologically activating
HIF target genes (Ang et al, 2002). The mutation is endemic to
Chuvashia and also to the Italian island of Ischia (Sergeyeva
et al, 1997; Perrotta et al, 2006), and has been identiﬁed as
a cause of congenital polycythaemia in individuals from many
other ethnic backgrounds (Percy, 2007). With the exception of
one individual, in all cases the VHL 598C>T mutation has been
associated with the same haplotype, indicating a common
founder (Percy, 2007). Patients usually present with symptoms
of polycythaemia in early adulthood or are diagnosed on
family screening, and are typically asymptomatic following
treatment with therapeutic venesection. Chuvash polycytha-
emia is associated with early mortality, due partly to throm-
botic complications, and carries a predisposition towards
benign vertebral body haemangiomas, varicose veins and low
systemic blood pressure (Gordeuk et al, 2004). The condition
has features of both primary and secondary polycythaemia, as
serum Epo is inappropriately raised yet erythroid progenitors
are also hypersensitive to Epo (Ang et al, 2002). Over-
expression of many HIF-regulated gene products has been
documented, including Epo, vascular endothelial growth
factor, glucose uptake transporter-1, transferrin, transferrin
receptor, plasminogen activator inhibitor-1, aldolase C and
endothelin-1 (Ang et al, 2002; Gordeuk et al, 2004; Bushuev
et al, 2006; Smith et al, 2006).
In addition to the Chuvash mutation, several other VHL
mutations have also been associated with congenital poly-
cythaemias (Percy, 2007), and it has been stated that VHL
mutations represent the most frequent cause of congenital
polycythaemia (Gordeuk et al, 2005). These polycythaemia-
associated mutations do not overlap with the many VHL
mutations that are known to cause the classic VHL cancer
syndrome, which is an entirely distinct disease and is only
rarely complicated by polycythaemia (Lonser et al, 2003).
Another form of familial polycythaemia caused by dysregula-
tion of HIF signalling has recently been identiﬁed (Percy et al,
2006). In three related individuals, a novel mutation in EGLN1
(which encodes PHD2) was associated with polycythaemia and
inappropriately normal levels of Epo. Several further EGLN1
mutations associated with polycythaemia have since been
described in unrelated individuals (Al-Sheikh et al, 2007; Percy
et al, 2007). Heterozygosity for these mutations appears to
reduce the functional activity of PHD2 (Percy et al, 2006),
which is the principal PHD isoenzyme regulating the low
steady-state level of HIF-a under euoxic conditions (Berra
et al, 2003).
These rare manifestations of genetic disease together con-
ﬁrm the importance of the PHD-VHL-HIF axis in controlling
Epo expression and thus red cell mass in humans. However,
the response to Epo stimulation is dependent upon mainte-
nance of sufﬁcient marrow availability of rate-limiting sub-
strates. Though Hb is increased within a week of ascent to high
altitude, some authors have observed a transient fall in Hb over
the following 1–2 weeks, when serum ferritin is sharply
lowered (Richalet et al, 1994). These authors suggest that this
fall in Hb results from intercurrent iron deﬁciency and
consequent marrow resistance to Epo, and that the poly-
cythaemic response resumes upon restoration of adequate iron
availability (Richalet et al, 1994). It is therefore not surprising
that hypoxia has long been known to increase intestinal iron
absorption in humans adapting to high altitude (Reynafaire &
Ramos, 1961) and that HIF promotes iron transport by
up-regulating transferrin (Rolfs et al, 1997) and the transferrin
receptor (Lok & Ponka, 1999; Tacchini et al, 1999). However,
the coordinated mechanism through which hypoxia-induced
erythropoietic iron demands are met has only recently been
elucidated.
Though better known for inducing the expression of its
transcriptional targets, HIF also represses a small number of
genes (eg Chen et al, 2005). Recent experiments in genetically
engineered mice have shown that HIF negatively regulates
hepcidin, the key hormonal regulator of iron homeostasis
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and inhibits active transmembrane export of iron by blocking
ferroportin, the sole iron-transporter responsible for iron
efﬂux from enterocytes and macrophages (Nemeth et al,
2004). Down-regulation of hepcidin liberates ferroportin,
thereby increasing intestinal iron absorption and mobilising
recycled iron from macrophages (Ganz, 2006). Through the
stabilisation of HIF-a, hypoxia and iron-deﬁciency both
suppress hepcidin and thereby increase iron availability, at
least in mice (Peyssonnaux et al, 2007). Similar involvement of
HIF in humans seems likely, as hepcidin is likewise critical to
human iron homeostasis – indeed, hepcidin deﬁciency under-
lies most forms of the iron-overload disorder hereditary
haemochromatosis (Ganz, 2006). Thus, it appears that HIF
simultaneously stimulates the polycythaemic response to
hypoxia and boosts the availability of iron so as to meet the
resultant erythropoietic demands.
Iron and HIF are further coupled through the action of
iron regulatory proteins IRP1 and IRP2. IRPs post-transcrip-
tionally regulate the expression of several proteins of iron
metabolism by binding to their mRNA iron-responsive
elements (IREs). When iron is scarce, IRP-IRE binding
promotes cellular iron uptake and prevents iron sequestration
by stabilising transferrin receptor mRNA and inhibiting the
translation of ferritin mRNA. In contrast, in iron-replete cells
IRP1 is biochemically inactivated and IRP2 undergoes iron-
dependent proteasomal degradation, resulting in reduced IRE-
binding activity and opposite homeostatic effects. It is
interesting to note that it has been proposed that the IRP2
degradation pathway involves an unidentiﬁed 2-oxoglutarate-
dependent dioxygenase from the same family as the HIF
hydroxylases (Wang et al, 2004), although VHL is not
a necessary component of this pathway (Wang & Panto-
poulos, 2005). Furthermore, it has recently been reported that
HIF-2a is post-translationally regulated by IRP-IRE binding
(Sanchez et al, 2007). Since HIF-2a appears to be the most
important HIF isoform in regulating Epo (Rankin et al, 2007),
this introduces a negative-feedback control mechanism that
may operate during iron-deﬁciency to limit Epo stimulation
of erythropoiesis until iron availability is sufﬁcient to allow
effective red blood cell production.
HIF and ventilation
Ventilatory responses to acute hypoxia are mediated by the
glomus cells of the carotid body. Though the precise oxygen-
sensing mechanism has yet to be determined, it is generally
accepted that hypoxic inhibition of potassium channels leads
to membrane depolarisation, calcium inﬂux, release of neuro-
transmitters and stimulation of sensory nerves that activate the
respiratory centre of the brain (Weir et al, 2005). The control
of ventilation is not well understood, and the underlying
biology of ventilatory acclimatisation to hypoxia remains
a subject of debate. However, the hypothesis now gaining most
credence contends that ventilatory acclimatisation is driven by
hypoxia-induced changes in carotid body function that involve
oxygen-regulated alterations in gene expression (Robbins,
2007). A recent set of experiments conducted in patients with
Chuvash polycythaemia strongly implicate HIF in the control
of ventilation (Smith et al, 2006).
Three venesected subjects with Chuvash polycythaemia were
compared with matched ‘normal’ healthy control subjects, and
with venesected ‘polycythaemic’ control subjects who had each
been diagnosed with forms of polycythaemia unrelated to
oxygen-sensing. While breathing air, average arterial Pco2 was
signiﬁcantly lower in the Chuvash polycythaemia patients,
indicating an altered set point for respiratory control in the
direction of an elevation in pulmonary ventilation. Cardio-
pulmonary responses to isocapnic hypoxia were assessed using
the technique of dynamic end-tidal forcing while subjects
breathed on a mouthpiece system. The ventilatory response
stimulated by acute hypoxia was several-fold greater in the
Chuvash polycythaemia patients than in controls for both mild
and moderate hypoxic stimuli. Thus, patients with Chuvash
polycythaemia had both a reduced Pco2 set point for the
respiratory controller and an abnormally high acute hypoxic
ventilatory sensitivity, which together are characteristic of
acclimatised individuals. These results strongly support the
notion that HIF is involved in human ventilatory acclimati-
sation to hypoxia, and establish the importance of HIF in
respiratory control in hypoxia-naı ¨ve individuals. Such involve-
ment of HIF is consistent with the nature of some of the genes
HIF is known to activate, most notably tyrosine hydroxylase,
which regulates the biosynthesis of catecholamine neurotrans-
mitters in the rat carotid body and brainstem respiratory
centre (Nguyen et al, 2007).
HIF and the pulmonary vasculature
The mechanism underlying hypoxic pulmonary vasoconstric-
tion is not completely understood, although it is known to
arise from the inherent properties of pulmonary arteriolar
smooth muscle cells and is modulated by a variety of endo-
thelial-derived vasoactive mediators. The initial sequence is
somewhat analogous to that of the carotid body glomus cells –
in contrast with smooth muscle cells from other vascular beds,
hypoxic inhibition of outward potassium current causes
depolarisation of the pulmonary arterial myocyte membrane,
resulting in calcium entry and subsequent contraction (Weir
et al, 2005). However, the oxygen sensor or sensors that
activate this sequence, and the ion channels and signal
transduction pathways involved, remain a source of much
scientiﬁc controversy (Aaronson et al, 2006).
In the same study of patients with Chuvash polycythaemia,
a standard echocardiographic technique was used to determine
pulmonary vascular tone at baseline and during exposure to
hypoxia (Smith et al, 2006). Chuvash polycythaemia patients
were found to have a degree of pulmonary hypertension, with
basal systolic pulmonary arterial pressures exceeding
30 mmHg. This result is consistent with other reports
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elevation in pulmonary arterial pressure (Smith et al, 2006).
The patients also displayed exquisite pulmonary vascular
sensitivity to hypoxia, with hypoxic responses 5- to 10-fold
greater than those of controls. Indeed, a moderate hypoxic
stimulus (end-tidal Po2 of 50 mmHg) provoked peak systolic
pulmonary arterial pressures exceeding 70 mmHg in the
patients, compared with less than 30 mmHg in the control
group. Several HIF-activated genes are important in vasomotor
regulation and may be involved in the pulmonary vascular
response to hypoxia (Schoﬁeld & Ratcliffe, 2004; Smith et al,
2006). The best studied of these is the vasoconstrictor
endothelin-1 (EDN1), which is elevated in patients with
Chuvash polycythaemia (Bushuev et al, 2006) and in the lungs
of patients with pulmonary hypertension (Giaid et al, 1993).
Variation within the PHD-VHL-HIF axis
The profound physiological disturbances associated with the
Chuvash mutation raise the question of whether common
genetic variation within the PHD-VHL-HIF axis might also
have phenotypic effects on physiological function. Such effects
might explain some of the considerable inter-individual
variation seen in Epo secretive (Richalet et al, 1994), ventila-
tory (Hirshman et al, 1975) and pulmonary vascular responses
(Groves et al, 1993) to hypoxia. It is therefore interesting that
speciﬁc polymorphic variants of HIF1A have been proposed to
be associated with maximal oxygen consumption during
exercise (Prior et al, 2003), and that certain HIF1A genotypes
have been reported to occur more frequently in the Sherpa
population of Tibet than in lowlanders (Liu et al, 2007).
However, a study of Andean high-altitude natives found no
associations between severe polycythaemia and polymor-
phisms of several genes involved in hypoxia sensing, including
the major components of the PHD-VHL-HIF axis (Mejia et al,
2005).
Another potential source of variation in HIF activity is iron
status. Iron is an obligate cofactor in the hydroxylation
reaction through which HIF is primarily regulated, and in
cultured cells HIF degradation is both inhibited by iron
chelation with DFO and potentiated by supraphysiological
iron supplementation (Wang & Semenza, 1993b; Knowles
et al, 2003). Iron availability might similarly affect HIF
degradation in humans and thereby inﬂuence HIF-dependent
processes. This appears to have been the case in the DFO
infusion experiments described previously, and it has been
suggested that in Chuvash polycythaemia, venesection-induced
iron deﬁciency could phenocopy the physiological manifesta-
tions of VHL loss of function to some extent (Smith et al,
2006). A further interesting possibility is suggested by the
observation that iron supplementation may increase the
incidence of pre-eclampsia – a disease postulated to be caused
by inadequate placental development (Ziaei et al, 2007). Iron-
induced down-regulation of HIF might in theory explain this
otherwise puzzling association (Smith & Robbins, 2007).
Conclusion
Hypoxic regulation of erythropoiesis provided the paradigm
through which HIF was discovered and initially investigated.
Convergent discoveries in the biochemistry of oxygen sensing
and in cardiopulmonary physiology have since established that
the PHD-VHL-HIF axis is important in regulating both
intracellular and systems-level human biology. The emerging
role of HIF in systemic physiology, described here in terms of
the response to high altitude, in fact translates to any clinical
scenario in which hypoxia is a feature. Functional differences
arising from common genetic variation or the availability of
cofactors, such as iron, may therefore inﬂuence the clinical
response to any such physiological or pathological disturbance.
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